Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emerging literature suggests that anti-PD-1 immunotherapy can counterintuitively enhance T reg cell numbers in a proportion of patients, driving resistance to immunotherapy.” ...

In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a major target in cancer immunotherapy. Now, Dr. Ishida and colleagues ...

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

In the 1/1.5 mg/kg dose group, median OS achieved 17.5 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2 α-bias bispecific immunotherapy.

SAN FRANCISCO and SUZHOU, China, June 1, 2025/ PRNewswire/-- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines ...